EMR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Emerson Electric is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 available. The business fundamentals are solid and the latest quarter showed healthy growth, but the stock is currently sitting near technical indecision with bearish momentum still present and no Intellectia buy signals active. My direct view: do not buy aggressively today; hold and wait for a clearer entry.
EMR closed at 140.52, slightly below the previous close of 141.09, with the broader session showing weakness. MACD histogram is negative and expanding, which points to short-term downside momentum. RSI_6 is near 51, so the stock is neutral rather than oversold. Moving averages are converging, suggesting a consolidation phase rather than a strong uptrend. Key levels: pivot 141.59, resistance 146.95 and 150.26, support 136.22 and 132.91. The current setup looks range-bound with mild near-term pressure, not an ideal immediate entry for an impatient buyer.
Underlying orders grew 5%, gross margin improved to 48.6%, and management raised the low end of FY26 EPS guidance while revising full-year sales growth expectations to 4.5%. Analysts like RBC and Jefferies turned more constructive, with price target increases and an Outperform/Buy view from RBC and Jefferies respectively. The company’s software and industrial automation strategy also gives it a longer-term growth narrative.
Price action is weak right now, with the stock down meaningfully in the latest regular session and momentum still negative. Analyst views are mixed, with Barclays and Wells Fargo staying cautious and Deutsche Bank issuing a Catalyst Call: Sell. Congress trading data shows one sale and no purchases in the last 90 days, which is a negative sentiment signal. The market is also digesting Middle East disruption exposure, which some analysts view as a near-term headwind.
Latest quarter: Q2 2026. Revenue increased to $4.562B, up 2.93% YoY. Net income rose to $618M, up 27.42% YoY. EPS increased to $1.10, up 27.91% YoY. Gross margin improved to 48.6%, up 0.56 percentage points YoY. Overall, the quarter was healthy, with profit growth outpacing revenue growth, which suggests improving operating efficiency and solid execution.
Analyst sentiment is mixed but improving overall. Recent upside revisions came from RBC ($169, Outperform), Jefferies ($175, Buy), Stephens ($155, Equal Weight), and Barclays ($144, Equal Weight). Bears remain present, especially Deutsche Bank's Catalyst Call: Sell and Wells Fargo's lowered target to $135. Net view: Wall Street is moderately constructive on the business, but not uniformly bullish on the stock at the current price. The pros like order momentum, margin improvement, and guidance resilience; the cons focus on near-term demand uncertainty, geopolitical exposure, and limited immediate upside from some firms' perspective.
